Compare AbbVie Inc (ABBV) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Skyworks Solutions Inc — how do they compare? AbbVie Inc trades at $247.91 (market cap $441.94B), while Skyworks Solutions Inc trades at $68 (market cap $10.28B). The key difference: AbbVie Inc is far larger — about 43× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| ABBV | SWKS | |
|---|---|---|
Market Cap | $441.94B | $10.28B |
Sector | Health | Technology |
52-Week High | $263.58 | $83.40 |
52-Week Low | $197.38 | $52.50 |
Enterprise Value | $506.19B | $10.16B |
Dividend Yield | 2.77% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Skyworks Solutions (SWKS) trades at $68.79, down 2.59% on the day, showing mixed technical signals with bullish moving averages but neutral oscillators. The company delivered three consecutive quarterly earnings beats, with Q3 2026 EPS of $1.08 exceeding expectations by $0.05. Revenue trends show contraction from $5.5B in 2022 to $4.1B in 2025, while profit margins declined from 23.24% to 11.67% over the same period. The pending Qorvo combination represents a significant strategic development, with regulatory approvals progressing and leadership teams announced.
The stock faces headwinds from revenue contraction and margin pressure, but strong institutional buying and analyst optimism (58% buy ratings) provide support. Key risks include integration challenges with Qorvo, ongoing margin compression, and mobile market concentration. Upside potential exists if the combination delivers synergies and AI data center growth accelerates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
